Gilead Sciences Inc. [GILD] stock Downgrade by BMO Capital Markets analyst, price target now $65


Gilead Sciences Inc. [NASDAQ: GILD] surged by $0.5 during the normal trading session on Monday and reaching a high of $62.39 during the day while it closed the day at $61.68. The company report on May 6, 2022 that Closing the Representation Gap in Schools, One Black Male Teacher at a Time.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Northampton, MA –News Direct– Gilead Sciences.

Codion Isom never had any teachers who looked like him growing up, and as a Black man he knows the importance of having Black male role models at a young age. That’s why he answered the call to play that role when he got older.

Gilead Sciences Inc. stock has also gained 2.27% of its value over the past 7 days. However, GILD stock has declined by -3.26% in the 3 months of the year. Over the past six months meanwhile, it has lost -7.00% and lost -15.05% year-on date.

The market cap for GILD stock reached $77.58 billion, with 1.25 billion shares outstanding and 1.25 billion shares in the current float. Compared to the average trading volume of 10.65M shares, GILD reached a trading volume of 9242149 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Gilead Sciences Inc. [GILD]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $69.52 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BMO Capital Markets have made an estimate for Gilead Sciences Inc. shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on February 28, 2022. While these analysts kept the previous recommendation, Wells Fargo dropped their target price from $72 to $70. The new note on the price target was released on February 02, 2022, representing the official price target for Gilead Sciences Inc. stock. Previously, the target price had yet another drop from $77 to $75, while Truist kept a Hold rating on GILD stock. On February 02, 2022, analysts decreased their price target for GILD shares from 87 to 85.

The Average True Range (ATR) for Gilead Sciences Inc. is set at 1.37, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 2.82. The Price to Book ratio for the last quarter was 3.88, with the Price to Cash per share for the same quarter was set at 4.23. Price to Free Cash Flow for GILD in the course of the last twelve months was 12.28 with Quick ratio for the last quarter at 1.30.

GILD stock trade performance evaluation

Gilead Sciences Inc. [GILD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.27. With this latest performance, GILD shares gained by 1.13% in over the last four-week period, additionally sinking by -7.00% over the last 6 months – not to mention a drop of -8.60% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 52.07, with the RSI for the last a single of trading hit 52.81, and the three-weeks RSI is set at 51.01 for Gilead Sciences Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 60.56, while it was recorded at 61.32 for the last single week of trading, and 66.86 for the last 200 days.

Gilead Sciences Inc. [GILD]: An insightful look at the core fundamentals

Gilead Sciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.50.

Earnings per share (EPS) analysis for Gilead Sciences Inc. [GILD] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences Inc. go to -1.55%.

Gilead Sciences Inc. [GILD]: Insider Ownership positions

There are presently around $62,346 million, or 83.50% of GILD stock, in the hands of institutional investors. The top three institutional holders of GILD stocks are: BLACKROCK INC. with ownership of 118,961,206, which is approximately -1.671% of the company’s market cap and around 0.10% of the total institutional ownership; CAPITAL RESEARCH GLOBAL INVESTORS, holding 107,156,981 shares of the stock with an approximate value of $6.56 billion in GILD stocks shares; and VANGUARD GROUP INC, currently with $6.47 billion in GILD stock with ownership of nearly 0.569% of the company’s market capitalization.

840 institutional holders increased their position in Gilead Sciences Inc. [NASDAQ:GILD] by around 53,834,551 shares. Additionally, 744 investors decreased positions by around 50,652,689 shares, while 189 investors held positions by with 914,572,783 shares. The mentioned changes placed institutional holdings at 1,019,060,023 shares, according to the latest SEC report filing. GILD stock had 171 new institutional investments in for a total of 3,588,832 shares, while 167 institutional investors sold positions of 5,995,809 shares during the same period.